Goldman Sachs cuts its price target on NuVasive (NUVA -4.2%) to $14 from $17 and lowers its EPS...
Goldman Sachs cuts its price target on NuVasive (NUVA -4.2%) to $14 from $17 and lowers its EPS outlook to reflect the $37M redemption of convertible debt the medical device company announced earlier this week as well as reduced estimates for the U.S. spine market.
From other sites
at CNBC.com (Oct 4, 2012)
at CNBC.com (Oct 3, 2012)
at CNBC.com (Jun 28, 2012)
at CNBC.com (Jun 23, 2010)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs